Details

Autor(en) / Beteiligte

• Peng, Wanren
• Zhang, Fenglin
• Wang, Zishu
• Li, Dongliang
• He, Yifu
• Ning, Zhongliang
• Sheng, Lili
• Wang, Jidong
• Xia, Xiaoyang
• Yu, Changjun
• Wang, Zian
• Zhao, Yong
• Liang, Hui
• Hu, Bing
• Sun, Cuiling
• Wang, Daoqin
• Cheng, Yunsheng
• Pan, Ming
• Xia, Liming
• Guo, Xinglai
• Zhang, Yanshun
• Hu, Zhiqiang
• Li, Xinzhong
• Lu, Lin
• Zhang, Jun
• Qian, Hong
• Xie, Hua
• Sun, Guoping

Titel

Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China

Ist Teil von

• Cancer management and research, 2020-01, Vol.12, p.6977-6985

Ort / Verlag

New Zealand: Dove Medical Press Limited

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• In China, gastric cancer (GC) ranks second in incidence and mortality. Over 80% of patients with GC were diagnosed at an advanced stage with poor clinical outcome. Chemotherapy was the mainstream treatment with limited benefit. Apatinib, an inhibitor of targeting vascular endothelial growth factor receptor 2 (VEGFR2), has been approved for third-line treatment of advanced gastric cancer. However, the data of apatinib treatment in the real-world setting are limited. In this real-world study, we aimed to understand the current treatment pattern of apatinib, investigate the effectiveness and safety of apatinib in real-world settings, and explore the potential factors associated with the clinical outcomes. This was a prospective, multicenter observational study in a real-world setting. Patients aged ≥18 years with histologic diagnosis of advanced GC were eligible for enrollment. The eligible patients received either apatinib monotherapy or apatinib plus chemotherapy by physician's discretion. Apatinib treatment could be used as first-line, second-line, or third-line and above therapy. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS), ORR, DCR, and safety profile. A total of 737 patients with advanced gastric cancer treated with apatinib were included in the FAS population. A total of 54.9% patients used apatinib monotherapy and 45.1% patients used apatinib combination therapy. A total of 44.1% patients received apatinib in first-line treatment, 28.2% in second-line, and 27.7% in third-line and above. In first-line treatment, the objective response rate (ORR) was 9.09% and 16.42% in apatinib monotherapy and combination therapy groups, and disease control rate (DCR) was 78.41% and 89.29%, respectively. Patients who received combination therapy achieved significantly longer median progression-free survival (mPFS; 6.18 vs 3.52 months, <0.01) and median overall survival (mOS; 8.72 vs 5.92 months, <0.01) compared with monotherapy. In second-line and third-line therapy, combination therapy showed a better trend in tumor response and survival outcomes compared with monotherapy. For all patients, apatinib combined with paclitaxel were associated with longer mPFS compared with other combinations (8.88 vs 6.62 months). Multivariate analysis showed that combination with paclitaxel ( =0.02) and experience of apatinib-related specific AEs ( <0.01) were independent predictors for PFS and OS. The safety profile was tolerable and no unexpected adverse events were reported. In a real-world setting, apatinib showed a favorable effectiveness and safety profile in patients with advanced gastric cancer. Apatinib combination therapy, especially combined with paclitaxel, might lead to better survival benefit in first-line treatment. Combination with paclitaxel and the occurrence of apatinib-specific AEs were independent factors associated with better survival outcomes. NCT03333967.